spartalizumab (PDR001) / Novartis 
Welcome,         Profile    Billing    Logout  
 0 Diseases   43 Trials   43 Trials   592 News 
31 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
spartalizumab (PDR001) / Novartis
COMBI-i, NCT02967692 / 2016-002794-35: A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Checkmark From COMBI-i trial in combination with Tafinlar and Mekinist for BRAFV600 metastatic melanoma at ESMO 2020
Sep 2020 - Sep 2020: From COMBI-i trial in combination with Tafinlar and Mekinist for BRAFV600 metastatic melanoma at ESMO 2020
Checkmark From COMBI-i trial in combination with Tafinlar and spartalizumab for BRAFV600 metastatic melanoma
Sep 2020 - Sep 2020: From COMBI-i trial in combination with Tafinlar and spartalizumab for BRAFV600 metastatic melanoma
Checkmark From COMBI-i trial in combination with spartalizumab and Mekinist for BRAFV600 metastatic melanoma
More
Active, not recruiting
3
569
Europe, Canada, Japan, US, RoW
Spartalizumab, PDR001, Placebo, Dabrafenib, Trametinib
Novartis Pharmaceuticals
Melanoma
08/20
08/24
NCT04229004: A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Active, not recruiting
3
825
US
Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
Pancreatic Cancer Action Network
Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
06/27
06/27
2020-003022-22: SOLTI-1904: EfficACy of Spartalizumab acROss multiPle cancer-types in patients with PD1-high mRNA expressing tumOrs defined by a singLe and pre-specIfied cutoff (ACROPOLI trial) SOLTI-1904: Eficacia de spartalizumab en múltiples tipos de cáncer en pacientes con tumores con expresión elevada de ARNm de PD1, definida según un punto de corte preespecificado (ensayo ACROPOLI)

Not yet recruiting
2
141
Europe
Spartalizumab, PDR001, Concentrate for solution for infusion
SOLTI, Novartis Pharma AG
Metastatic disease Enfermedad metastásica, Metastatic disease Enfermedad metastásica, Diseases [C] - Cancer [C04]
 
 
NCT03785496: Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus

Active, not recruiting
2
44
RoW
PDR001
Yonsei University
Histologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment
01/22
01/24
NCT03668431: Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

Recruiting
2
25
US
Dabrafenib, Tafinlar®, Trametinib, Mekinist®, PDR001
Massachusetts General Hospital, Novartis, Stand Up To Cancer
Metastatic Colorectal Cancer
09/22
12/22
NCT04323436 / 2019-003097-11: Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Terminated
2
31
Europe, Canada, Japan, US, RoW
Spartalizumab, PDR001, Capmatinib, INC280, spartalizumab placebo, PDR001 placebo
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
12/22
01/23
CNIR178X2201, NCT03207867 / 2017-000241-49: A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Terminated
2
315
Europe, Japan, US, RoW
NIR178, taminadenant, PDR001, spartalizumab
Novartis Pharmaceuticals
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
02/23
02/23
ALTER-PATH NeoDT, NCT04310397: Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Completed
2
4
US
Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Spartalizumab, PDR-001, PDR001, Therapeutic Conventional Surgery, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
M.D. Anderson Cancer Center
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
10/23
10/23
SPARTANA, NCT04894370: Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma

Recruiting
2
34
Europe
Sample collection
Centre Hospitalier Universitaire de Besancon, National Cancer Institute, France, Novartis
Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma
06/25
11/26
GASPAR, NCT04736485 / 2020-004497-21: Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)

Active, not recruiting
2
67
Europe
perioperative treatment
Centre Francois Baclesse, National Cancer Institute, France
Gastric Cancer by AJCC V8 Stage, Resectable Carcinoma
03/24
03/27
daNIS-1, NCT04390763 / 2020-000349-14: Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Terminated
2
164
Europe, US, RoW
NIS793, Spartalizumab, PDR001, gemcitabine, nab-paclitaxel, abraxane
Novartis Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma
04/24
05/24
NCT04544111: PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Active, not recruiting
2
19
US
Trametinib, Dabrafenib, PDR001
Memorial Sloan Kettering Cancer Center
Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer, Follicular Thyroid Cancer, Hurthle Cell Tumor, Poorly Differentiated Thyroid Gland Carcinoma, Hurthle Cell Thyroid Neoplasia
09/25
09/25
ACROPOLI, NCT04802876: Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors

Recruiting
2
184
Europe
Spartalizumab, PDR001, Tislelizumab
SOLTI Breast Cancer Research Group, Novartis
MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma, Mesothelioma, Triple Negative Breast Cancer, Lung Adenocarcinoma, Cholangiocarcinoma, Cervical Carcinoma, Kidney Clear Cell Carcinoma, Stomach Adenocarcinoma, Esophageal Adenocarcinoma, Uterine Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Sarcoma, Lung Squamous Cell Carcinoma, Urothelial Carcinoma, Thyroid Carcinoma, Hepatocellular Carcinoma, Uveal Melanoma, HER2-positive Breast Cancer, Pancreatic Adenocarcinoma, Squamous Esophageal Carcinoma, Epithelial Ovarian Cancer, Uterine Carcinosarcoma, Small Cell Lung Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer, Lung Adenocarcinoma EGFR-mutated/ ALK Traslocation, Colorectal Adenocarcinoma, Prostate Adenocarcinoma, Carcinoma of Unknown Primary, Other Histology
09/25
03/27
NCT05201066: Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Recruiting
2
70
Europe, US, RoW
decitabine, spartalizumab, PDR001, sabatolimab, MBG453, azacitidine, venetoclax, INQOVI (oral decitabine)
Novartis Pharmaceuticals
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
09/27
02/28
NCT04191421: Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Completed
1/2
42
US
Siltuximab, Anti-IL-6 Chimeric Monoclonal Antibody, cCLB8, CNTO 328, Sylvant, Spartalizumab, PDR001
Emory University, Novartis, EUSA Pharma, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
04/23
04/23
SPARTO, NCT05210413: Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults

Recruiting
1/2
59
Europe
Spartalizumab in Pediatric cohort, Low-dose Pazopanib in Pediatric Cohort, Spartalizumab in Adult cohort, Low-dose Pazopanib in Adult Cohort
University Hospital, Bordeaux, National Cancer Institute, France, Fondation ARC, Novartis
Refractory or Recurrent Solid Tumor
11/26
11/27
PanCAN-SR1, NCT04581343: A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients

Checkmark Results from PanCAN-SR1 trial for metastatic pancreatic ductal adenocarcinoma
Nov 2022 - Nov 2022: Results from PanCAN-SR1 trial for metastatic pancreatic ductal adenocarcinoma
Active, not recruiting
1b
10
US
Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine, Ilaris, Abraxane
Pancreatic Cancer Action Network, Novartis Pharmaceuticals
Metastatic Pancreatic Ductal Adenocarcinoma
03/23
08/23
CPDR001X2105, NCT03066648: Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Checkmark Data from P1b portion of trial in combination with MBG453 and decitabine for AML/MDS at EHA 2020
Jun 2020 - Jun 2020: Data from P1b portion of trial in combination with MBG453 and decitabine for AML/MDS at EHA 2020
Checkmark In combination with PDR001 for AML or high risk MDS
Feb 2017 - Feb 2017: In combination with PDR001 for AML or high risk MDS
Completed
1b
241
Europe, US, RoW
Decitabine, 5-aza-2'-deoxycytidine, PDR001, spartalizumab, MBG453, sabatolimab, Azacitidine, 5-azacytidine
Novartis Pharmaceuticals
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Preleukemia, Bone Marrow Diseases, Hematologic Diseases, Chronic Myelomonocytic Leukemia
09/23
09/23
NCT01351103: A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Active, not recruiting
1
185
Europe, Canada, US
LGK974, WNT974, PDR001
Novartis Pharmaceuticals
Pancreatic Cancer, BRAF Mutant Colorectal Cancer, Melanoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Cancer, Cervical Squamous Cell Cancer, Esophageal Squamous Cell Cancer, Lung Squamous Cell Cancer
06/21
06/24
NCT03961971: Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Active, not recruiting
1
16
US
MBG453, spartalizumab, stereotactic radiosurgery
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Novartis Pharmaceuticals
Glioblastoma Multiforme
11/22
09/25
NCT03742349: Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Terminated
1
64
Europe, Japan, US, RoW
spartalizumab, PDR001, LAG525, NIR178, capmatinib, INC280, MCS110, canakinumab, ACZ885
Novartis Pharmaceuticals
Triple Negative Breast Cancer (TNBC)
02/23
02/23
NCT04237649: KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Terminated
1
77
Europe, Canada, Japan, US, RoW
KAZ954, PDR001, NIR178, NZV930
Novartis Pharmaceuticals
Solid Tumors
09/23
09/23
NCT04261439: A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Terminated
1
60
Europe, Japan, US, RoW
NIZ985, Spartalizumab, PDR001, Tislelizumab, VDT482
Novartis Pharmaceuticals
In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer
12/23
12/23
NCT04000529: Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Terminated
1
122
Europe, Japan, US, RoW
TNO155, Spartalizumab, PDR001, Ribociclib, LEE011
Novartis Pharmaceuticals
Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC, Gastrointestinal Stromal Tumors, Colorectal Cancer
01/24
01/24
RISE-HN, NCT04213404: Ribociclib and Spartalizumab in R/M HNSCC

Active, not recruiting
1
13
RoW
Ribociclib, Kisqali, Spartalizumab, PDR001
National Taiwan University Hospital, Novartis
Head and Neck Squamous Cell Carcinoma
01/24
01/25
NCT03891953: Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

Active, not recruiting
1
98
Europe, Japan, US, RoW
DKY709, PDR001, Spartalizumab
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma, Microsatellite Stable Colorectal Cancer, Triple Negative Breast Cancer
09/24
09/24
NCT04294160: A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Active, not recruiting
1
122
Europe, Canada, US, RoW
Dabrafenib, DRB436, Tafinlar, LTT462, Trametinib, TMT212, Mekinist, LXH254, TNO155, Spartalizumab, PDR001, Tislelizumab, VDT482, BGBA317
Novartis Pharmaceuticals
BRAF V600 Colorectal Cancer
10/24
10/24
NCT02936102: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Active, not recruiting
1
154
Europe, Canada, Japan, US, RoW
FAZ053, PDR001
Novartis Pharmaceuticals
Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma
11/24
11/24
CDFF332A12101, NCT04895748 / 2020-004383-25: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Active, not recruiting
1
40
Europe, Japan, US, RoW
DFF332, RAD001, Everolimus, PDR001, Spartalizumab, NIR178, Taminadenant
Novartis Pharmaceuticals
Carcinoma, Renal Cell
02/25
02/25
SPARC-1, NCT04028245: A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma

Recruiting
1
14
US
Spartalizumab, PDR-001, Canakinumab, ACZ885
Columbia University, Novartis
Carcinoma, Renal Cell
12/25
12/26
NCT04058756: Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Active, not recruiting
1
120
Europe, Canada, US, RoW
PDR001
Novartis Pharmaceuticals
Advanced Solid Tumors
04/30
04/30

Download Options